Bringing possibility to Duchenne.

6-2-hero-liam.

Meet Liam, age 19
Deletion of exons 48-50

graysen

Meet Graysen, age 2
Deletion of exons 48-50

Micah

Meet Micah, age 8
Deletion of exon 50

Ryan

Meet Ryan, age 11
Deletion of exons 48-50

EXONDYS 51 is the first FDA-approved Duchenne muscular dystrophy treatment for patients who have a confirmed genetic mutation in the dystrophin gene that can be treated by skipping exon 51. In some patients, it helps the body make a shorter form of the dystrophin protein.

Approved under accelerated approval.
Accelerated approval allows for drugs to be approved based on a marker that is considered reasonably likely to predict a clinical benefit. EXONDYS 51 treatment increased the marker, dystrophin, in skeletal muscle in some patients. Verification of a clinical benefit may be needed for EXONDYS 51 to continue to be approved.

Who can take it?

Learn the importance of understanding your genetic mutation and what it means to be amenable to treatment with EXONDYS 51.

Learn About Amenability

Starting Treatment

Starting treatment with EXONDYS 51? Let us take you through the process so you know what to expect.

Explore the Process

Getting Support

With the SareptAssist patient support program, we'll help you navigate the process of starting therapy with EXONDYS 51.

How We Can Help

Graysen

"My son, Zyler, has Duchenne. Any mother with a son with Duchenne wants to do anything they can to get access to medication. SareptAssist guided us every step of the way."

Holly, Zyler's mom

Zyler

 

 

Ongoing support and information from Sarepta.

Sign Up

Image
icon-signup-tips

Receive future tips and support about treatment with EXONDYS 51.

Image
 icon-signup-informed

Stay informed on SareptAssist services.

Image
icon-signup-meetings

Find out about patient resources that are available.

Image
icon-signup-updates

Get updates about news and research on Duchenne from Sarepta.

 

 

WHAT IS EXONDYS 51 (eteplirsen)?

EXONDYS 51 is used to treat Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation in the dystrophin gene that can be treated by skipping exon 51. EXONDYS 51 was approved under accelerated approval. Accelerated approval allows for drugs to be approved based on a marker that is considered reasonably likely to predict a clinical benefit. EXONDYS 51 treatment increased the marker, dystrophin, in skeletal muscle in some patients. Verification of a clinical benefit may be needed for EXONDYS 51 to continue to be approved.

Read More

IMPORTANT RISK INFORMATION

Allergic reactions, including wheezing, chest pain, cough, rapid heart rate, and hives have occurred in patients who were treated with EXONDYS 51. Seek immediate medical care if signs and symptoms of allergic reactions occur.

Side effects that happened at least 25% more often in 8 patients treated with EXONDYS 51 by intravenous infusion than in 4 patients treated with an inactive intravenous infusion were problems with balance (38%, 0%), vomiting (38%, 0%), and skin irritation (25%, 0%). The most common side effects were problems with balance and vomiting.

The most common side effects seen in greater than 10% of patients receiving EXONDYS 51 (N=163) in other clinical trials were headache, cough, rash, and vomiting. 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).

Please see the full Prescribing Information for EXONDYS 51 (eteplirsen).